Payment overview · 2025
General Payments
$401.78
21 reported records · 13 companies
Healthcare provider profile · identity verified
Ronald Edwin Calhoun, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · STEVENSON, AL · NPI 1942210745
Verified facts
What the public records show
CMS Open Payments records show Ronald Edwin Calhoun, M.D. received $401.78 in general payments during 2025 across 21 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Relistor, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 394 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Relistor by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $66.59 | 16.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.79 | 14.6% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $49.04 | 12.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.37 | 10.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.83 | 9.7% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $26.20 | 6.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.17 | 6.0% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $22.18 | 5.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.43 | 3.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.07 | 3.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.83 | 3.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.78 | 3.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.50 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $401.78 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.79 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $50.40 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $49.04 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $42.37 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $38.83 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 184 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 394 | exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
184 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
141 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
394 | 64 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 944 | 171 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 827 | 174 |
| Amlodipine Besylate | Amlodipine Besylate | 810 | 169 |
| Atorvastatin Calcium | Atorvastatin Calcium | 609 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 588 | 85 |
| Lisinopril | Lisinopril | 585 | 129 |
| Omeprazole | Omeprazole | 579 | 111 |
| Famotidine | Famotidine | 574 | 108 |
| Metformin Hcl | Metformin Hcl | 551 | 117 |
| Gabapentin | Gabapentin | 529 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 476 | 93 |
| Tamsulosin Hcl | Tamsulosin Hcl | 442 | 90 |
| Furosemide | Furosemide | 431 | 95 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 428 | 76 |
| Potassium Chloride | Potassium Chloride | 409 | 89 |
| Ozempic | Semaglutide | 394 | 64 |
| Ondansetron Odt | Ondansetron | 390 | 98 |
| Fluticasone Propionate | Fluticasone Propionate | 360 | 110 |
| Pregabalin | Pregabalin | 355 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 354 | 110 |
| Buspirone Hcl | Buspirone Hcl | 339 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 337 | 87 |
| Tizanidine Hcl | Tizanidine Hcl | 309 | 64 |
| Valsartan | Valsartan | 308 | 64 |
| Meloxicam | Meloxicam | 282 | 58 |
| Doxepin Hcl | Doxepin Hcl | 275 | 53 |
| Losartan Potassium | Losartan Potassium | 270 | 59 |
| Prednisone | Prednisone | 256 | 135 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 246 | 51 |
| Celecoxib | Celecoxib | 245 | 74 |
| Eliquis | Apixaban | 244 | 38 |
| Carvedilol | Carvedilol | 240 | 49 |
| Alprazolam | Alprazolam | 237 | 33 |
| Montelukast Sodium | Montelukast Sodium | 228 | 43 |
| Fluoxetine Hcl | Fluoxetine Hcl | 226 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 213 | 55 |
| Tramadol Hcl | Tramadol Hcl | 192 | 45 |
| Jardiance | Empagliflozin | 184 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 176 | 33 |
| Fluconazole | Fluconazole | 175 | 73 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 172 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 170 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 167 | 41 |
| Mirtazapine | Mirtazapine | 163 | 32 |
| Spironolactone | Spironolactone | 158 | 32 |
| Trazodone Hcl | Trazodone Hcl | 157 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 155 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 151 | 110 |
| Quetiapine Fumarate | Quetiapine Fumarate | 149 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 147 | 23 |
| Alendronate Sodium | Alendronate Sodium | 141 | 28 |
| Mounjaro | Tirzepatide | 141 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 29 |
| Simvastatin | Simvastatin | 137 | 38 |
| Estradiol | Estradiol | 134 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 28 |
| Januvia | Sitagliptin Phosphate | 130 | 22 |
| Allopurinol | Allopurinol | 129 | 29 |
| Aripiprazole | Aripiprazole | 120 | 19 |
| Methocarbamol | Methocarbamol | 118 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 117 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 112 | 26 |
| Sertraline Hcl | Sertraline Hcl | 109 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 108 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 107 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 26 |
| Promethazine Hcl | Promethazine Hcl | 104 | 30 |
| Clonazepam | Clonazepam | 97 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 94 | 18 |
| Propranolol Hcl | Propranolol Hcl | 91 | 17 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 84 | 12 |
| Bupropion Xl | Bupropion Hcl | 84 | 21 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 84 | 14 |
| Meclizine Hcl | Meclizine Hcl | 82 | 23 |
| Finasteride | Finasteride | 79 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 14 |
| Donepezil Hcl | Donepezil Hcl | 76 | 13 |
| Primidone | Primidone | 75 | 11 |
| Sucralfate | Sucralfate | 74 | 26 |
| Glipizide Er | Glipizide | 71 | 12 |
| Warfarin Sodium | Warfarin Sodium | 70 | suppressed |
| Lorazepam | Lorazepam | 69 | 11 |
| Movantik | Naloxegol Oxalate | 69 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 68 | 11 |
| Metformin Hcl Er | Metformin Hcl | 65 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | suppressed |
| Trimethoprim | Trimethoprim | 62 | suppressed |
| Glipizide | Glipizide | 61 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 57 | 14 |
| Atenolol | Atenolol | 54 | 12 |
| Farxiga | Dapagliflozin Propanediol | 53 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 52 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 37 |
| Nystatin | Nystatin | 50 | 33 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | suppressed |
| Colchicine | Colchicine | 48 | 23 |
| Valacyclovir | Valacyclovir Hcl | 48 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 46 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | 16 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Vraylar | Cariprazine Hcl | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 42 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Repatha Sureclick | Evolocumab | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 41 | 11 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Belsomra | Suvorexant | 37 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 29 |
| Ibuprofen | Ibuprofen | 36 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Lactulose | Lactulose | 34 | 14 |
| Topiramate | Topiramate | 34 | suppressed |
| Linzess | Linaclotide | 33 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 21 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 22 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 23 |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Relistor | Methylnaltrexone Bromide | 23 | suppressed |
| Ubrelvy | Ubrogepant | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 19 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Indomethacin | Indomethacin | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Ursodiol | Ursodiol | 21 | suppressed |
| Metronidazole | Metronidazole | 20 | 18 |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Cilostazol | Cilostazol | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $401.78 · 21 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | Auvelity, BRIXADI, CAPLYTA, INSPIRE, JARDIANCE, Korlym, OTEZLA, Ozempic, RELISTOR, REPATHA, REXULTI, Rybelsus, SUBLOCADE, TRULANCE, VOQUEZNA, Veozah, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error